12967_2016_877_MOESM4_ESM.docx (27.74 kB)
MOESM4 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
journal contribution
posted on 2016-05-06, 05:00 authored by Filippo Pietrantonio, Rosa Berenato, Claudia Maggi, Marta Caporale, Massimo Milione, Federica Perrone, Elena Tamborini, Dario Baratti, Shigeki Kusamura, Luigi Mariani, Monica Niger, Alessia Mennitto, Annunziata Gloghini, Ilaria Bossi, Giulio Settanni, Adele Busico, Pietro Bagnoli, Maria Di Bartolomeo, Marcello Deraco, Filippo de BraudAdditional file 4: Table S1. Genomic alterations detected in the 3 GNAS mutated colorectal cancer and matched clinical-pathological data.